Plus Therapeutics, Inc. (PSTV)

Plus Therapeutics, Inc. (PSTV) Healthcare & Pipeline Overview

Plus Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted radiotherapeutics for central nervous system cancers. Their lead candidate, Rhenium-186 NanoLiposome, aims to address unmet needs in treating recurrent glioblastoma and leptomeningeal metastases, positioning them in a niche market within the broader oncology landscape.

What Is the Investment Thesis for PSTV?

Plus Therapeutics presents a high-risk, high-reward investment opportunity centered on its lead drug candidate, Rhenium-186 NanoLiposome (186RNL). The company's focus on central nervous system cancers, particularly recurrent glioblastoma and leptomeningeal metastases, addresses a critical unmet need. Positive clinical trial results for 186RNL could drive significant value, given the limited treatment options currently available for these aggressive cancers. The company's high gross margin of 91.5% suggests strong potential profitability if the drug is successfully commercialized. A key risk lies in the inherent challenges of clinical-stage drug development, including the possibility of trial failures or regulatory hurdles. The company's negative profit margin of -429.4% highlights its reliance on future revenue streams and the need for continued funding. Upcoming clinical trial data releases will be critical catalysts for the stock. Successful execution of clinical trials and subsequent regulatory approvals are essential for realizing the company's potential value.

Based on FMP financials and quantitative analysis

PSTV Key Highlights

• Lead drug candidate Rhenium-186 NanoLiposome targets cancers of the central nervous system, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
• Gross margin of 91.5% indicates strong potential profitability upon successful commercialization of Rhenium-186 NanoLiposome.
• Market capitalization of $9.80M reflects the company's early stage and associated risks.
• License agreement with NanoTx, Corp. expands pipeline and therapeutic potential in glioblastoma treatment.
• Beta of 1.02 indicates the stock's volatility is similar to the overall market.

Who Are PSTV's Competitors?

PSTV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PSTV's Key Strengths?

• Patented Rhenium-186 NanoLiposome technology.
• Focus on underserved market of central nervous system cancers.
• High gross margin potential.
• Experienced management team.

What Are PSTV's Weaknesses?

• Clinical-stage company with no approved products.
• Limited financial resources.
• High dependence on the success of Rhenium-186 NanoLiposome.
• Small team size.

What Could Drive PSTV Stock Higher?

• Data readouts from ongoing clinical trials of Rhenium-186 NanoLiposome in recurrent glioblastoma.
• Potential FDA regulatory milestones, including Fast Track designation or Breakthrough Therapy designation.
• Progress in securing strategic partnerships for co-development and commercialization.
• Expansion of the Rhenium-186 NanoLiposome pipeline into additional cancer indications.

What Are the Key Risks for PSTV?

• Financial-distress signal — its Altman Z-Score of -36.58 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory setbacks or rejection of drug applications.
• Competition from established pharmaceutical companies with greater resources.
• Dependence on securing additional funding to support operations.
• Patent expiration and loss of exclusivity.

What Are the Growth Opportunities for PSTV?

• Expansion of Rhenium-186 NanoLiposome into Additional Indications: Plus Therapeutics can explore the use of Rhenium-186 NanoLiposome in treating other types of cancers beyond recurrent glioblastoma and leptomeningeal metastases. This includes investigating its potential in other solid tumors or hematological malignancies where targeted radiotherapy could offer a therapeutic advantage. The market for cancer therapies is vast, with global oncology sales projected to reach hundreds of billions of dollars annually. Success in expanding the drug's application could significantly increase Plus Therapeutics' revenue potential.
• Strategic Partnerships and Collaborations: Forming partnerships with larger pharmaceutical companies or research institutions can provide Plus Therapeutics with access to additional resources, expertise, and funding. Collaborations can accelerate the development and commercialization of Rhenium-186 NanoLiposome and other pipeline candidates. The pharmaceutical industry is characterized by frequent collaborations, with deal values often reaching hundreds of millions or even billions of dollars. Successful partnerships can enhance Plus Therapeutics' credibility and market reach.
• Advancements in NanoLiposome Technology: Continued innovation in NanoLiposome technology can improve the drug's efficacy, safety, and delivery. This includes optimizing the size, composition, and targeting capabilities of the nanoliposomes to enhance drug penetration and retention within the tumor microenvironment. Nanotechnology is a rapidly evolving field, with ongoing research focused on developing more sophisticated drug delivery systems. Improvements in NanoLiposome technology can provide Plus Therapeutics with a competitive edge.
• Orphan Drug Designation and Regulatory Incentives: Pursuing orphan drug designation for Rhenium-186 NanoLiposome in specific cancer subtypes can provide Plus Therapeutics with regulatory incentives, such as market exclusivity and tax credits. Orphan drug designation is granted to therapies targeting rare diseases or conditions, offering significant commercial advantages. The orphan drug market is a growing segment of the pharmaceutical industry, with attractive profit margins and reduced competition.
• Geographic Expansion: Expanding into new geographic markets, such as Europe and Asia, can increase the potential patient population for Rhenium-186 NanoLiposome. These markets have a growing demand for advanced cancer therapies, driven by an aging population and increasing healthcare spending. International expansion requires navigating different regulatory pathways and establishing distribution networks, but it can significantly broaden Plus Therapeutics' revenue base. The global market for cancer therapies is highly competitive, but successful geographic expansion can provide a sustainable competitive advantage.

What Opportunities Does PSTV Have?

• Expansion into new cancer indications.
• Strategic partnerships with larger pharmaceutical companies.
• Advancements in NanoLiposome technology.
• Orphan drug designation and regulatory incentives.

What Threats Does PSTV Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from established pharmaceutical companies.
• Patent expiration.

What Are PSTV's Competitive Advantages?

• Patented Rhenium-186 NanoLiposome technology provides a degree of exclusivity.
• Focus on niche market of central nervous system cancers limits direct competition.
• Proprietary manufacturing process for radiotherapeutic drugs creates a barrier to entry.
• Clinical data and regulatory approvals can establish a competitive advantage.

What Does PSTV Do?

Plus Therapeutics, Inc., founded in 1996 and headquartered in Austin, Texas, is a clinical-stage pharmaceutical company dedicated to developing, manufacturing, and commercializing innovative treatments for cancer and other diseases. Originally named Cytori Therapeutics, Inc., the company rebranded as Plus Therapeutics, Inc. in July 2019, signaling a strategic shift towards oncology-focused therapies. The company's core focus is on its lead drug candidate, Rhenium-186 NanoLiposome (186RNL), a patented radiotherapy designed to target cancers affecting the central nervous system. These include recurrent glioblastoma (rGBM), leptomeningeal metastases (LM), and pediatric brain cancers, all of which represent significant unmet medical needs. Plus Therapeutics' approach involves the direct delivery of 186RNL into the tumor or cerebrospinal fluid, leveraging the properties of nanoliposomes to enhance drug penetration and retention within the target area while minimizing systemic exposure. The company has a license agreement with NanoTx, Corp. to further develop and commercialize NanoTx's glioblastoma treatment, expanding its pipeline and therapeutic potential in this challenging cancer type. With a team of 21 employees, Plus Therapeutics is actively engaged in clinical trials to evaluate the safety and efficacy of 186RNL, seeking to establish it as a viable treatment option for patients with limited alternatives. The company's strategy centers on addressing cancers with high morbidity and mortality rates, aiming to improve patient outcomes and quality of life through targeted radiotherapeutic interventions.

What Products and Services Does PSTV Offer?

• Develops Rhenium-186 NanoLiposome, a patented radiotherapy for central nervous system cancers.
• Targets recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
• Manufactures radiotherapeutic drugs for clinical trials and potential commercialization.
• Conducts clinical trials to evaluate the safety and efficacy of Rhenium-186 NanoLiposome.
• Seeks regulatory approvals for its drug candidates from agencies like the FDA.
• Collaborates with other companies and research institutions to advance its pipeline.
• Focuses on cancers with high morbidity and mortality rates.

How Does PSTV Make Money?

• Develops and patents novel cancer therapies, primarily radiotherapeutics.
• Outlicenses or partners with other companies for commercialization and distribution.
• Generates revenue through potential future sales of approved drugs.
• Funds research and development through grants, equity financing, and partnerships.

What Industry Does PSTV Operate In?

Plus Therapeutics operates within the biotechnology industry, specifically focusing on oncology and targeted radiotherapeutics. The oncology market is experiencing substantial growth, driven by an aging population and advancements in cancer diagnostics and treatments. The competitive landscape includes established pharmaceutical companies and smaller biotech firms developing novel therapies for cancer. Plus Therapeutics differentiates itself through its focus on central nervous system cancers and its patented NanoLiposome technology for targeted drug delivery. The global brain tumor therapeutics market is projected to reach billions of dollars by 2030, highlighting the significant market opportunity for effective treatments like Rhenium-186 NanoLiposome.

Who Are PSTV's Key Customers?

• Hospitals and cancer centers that treat patients with central nervous system cancers.
• Oncologists and neuro-oncologists who prescribe cancer therapies.
• Patients diagnosed with recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
• Research institutions and pharmaceutical companies involved in cancer research and development.

Key Financial Metrics

Return on assets is -59.9%, showing how much profit it generates from its asset base. A current ratio of 2.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -45.3%, the inverse of the P/E and a quick read on earnings relative to price.

How Plus Therapeutics, Inc. Is Valued

Plus Therapeutics, Inc. carries a market capitalization of $9.80M, placing it in the micro-cap category. Relative to its peer group, PSTV's quantitative score of 17/100 is below the peer average of 77/100.

F-Score 2/9Financial Health

Plus Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -36.58 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Plus Therapeutics, Inc. revenue of about $6.2M for fiscal 2026, with EPS near $-3.98. The estimate reflects 3 contributing analysts.

Net buyingInsider Activity

Over the past six months, Plus Therapeutics, Inc. insiders filed 28 SEC Form 4 transactions — 5 sales and 23 purchases. On net that is roughly 2.8M shares acquired (about $516K) — insiders putting money in tends to read as conviction.

PSTV Financials

PSTV Latest News

PSTV Analyst Consensus

PSTV MoonshotScore

Plus Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources